

11:01 13 Aug 2020

MindMed expanding R&D presence in Europe with Dr Miri Halperin Wernli leading the charge

Mind Medicine (MindMed) Inc (NEO:MMED) (OTCQB:MMEDF) is expanding its presence in Europe by opening an operating subsidiary in Switzerland, and has appointed Dr Miri Halperin Wernli as president to direct the firm's clinical development strategy.

The New York City-based neuro-pharmaceutical company developing psychedelic medicines, said Dr Wernli will be expanding the clinical and scientific team in Europe. Her immediate leadership responsibilities center around the company's LSD microdosing program and Project Lucy, the LSD experiential therapy program for anxiety disorders.

Dr Wernli will also help implement R&D collaborations in Europe which include the company's partnership with the University Hospital Basel's Liechti Lab.

READ: MindMed seeks to harvest the power of psychedelics to treat mental health disorders

In a statement, Dr Wernli said: "I am very excited to help scale MindMed's R&D as we seek to prove to governments and society that psychedelic inspired medicines and therapies can play a vital role in addressing the growing global mental health and addiction crisis."

She added: "I passionately believe psychedelic inspired medicines and therapies have immense potential to redefine society's approach to mental health. Many mental health disorders appear to be interconnected which presents a unique opportunity to MindMed to innovate and create novel treatment paradigms for various severe and chronic mental health conditions which have poor and unsatisfactory therapeutic offerings at present."

Dr Wernli is a senior pharma and biomedical executive with over 30 years of strategic and operational leadership and a deep understanding of drug development in heavy regulated environments.

Dr Halperin Wernli has held senior positions in product development, R&D and strategic marketing in Switzerland and the US at companies like Merck & Co (NYSE:MRK), Sharp & Dohme, Roche Holdings AG (OTCMKTS:RHHBY) and Actelion Pharmaceuticals. In addition, Dr Wernli has clinical experience in child and adult psychiatry in hospital settings in Switzerland and Canada. She previously co-founded and led Creso Pharma, an Australian listed medical cannabis company with operations in Europe and Canada.

MindMed co-founder and co-CEO JR Rahn said Dr Wernli brings "a wealth of experience," and leadership to the company's approach for patients. "Her expertise will help us to continue to pioneer the fast-growing psychedelic inspired medicine market."

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Price: 3.09

Market Cap: \$1.01 billion

1 Year Share Price Graph



March 2020 August 2020 January 2021

Share Information

Code: MMEDF

Listing: OTCQB

52 week High Low
5.07 0.0833

Sector: Pharma & Biotech

Website: www.mindmed.co

Company Synopsis:

MindMed is a neuropharmaceutical drug development platform advancing medicines based on psychedelic substances through rigorous science and clinical trials. MindMed's mission is to discover, develop and deploy psychedelic inspired medicines that alleviate suffering and improve health.

action@proactiveinvestors.com

Follow her on Twitter: @UttaraProactive

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of MindMed named herein, including the promotion by the Company of MindMed in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).